Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 2Leukemia 2Unspecified Childhood Solid Tumor, Protocol Specific 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Sarcoma, Ewing 1Pinealoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic NUT Carcinoma 1Medulloblastoma 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Endodermal Sinus Tumor 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Embryonal 1

Interventions

Rituximab 4Vincristine 3Prednisone 3Filgrastim 3Etoposide 3Doxorubicin 3Cyclophosphamide 3prednylidene 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1ibrutinib 1etoposide phosphate 1deltacortene 1Ultrasonography 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Endoscopy 1Electrocardiography 1Echocardiography 1CT-P10 1Bronchoscopy 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, AIDS-Related × etoposide phosphate × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡